reglab/statecodes huggingface dataset:
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 3 - Prescription Drug Monitoring Program (216-RICR-20-20-3) › Section 216-RICR-20-20-3.3 - Definitions

Current through June 14, 2024
A. Wherever used in these regulations, the
				  following terms shall be construed as follows:
1. "Controlled substance" means a drug,
				  substance, or immediate precursor in Schedules I-V of R.I. Gen. Laws Chapter
				  21-28 ("Uniform Controlled Substances Act"). The term shall not include
				  distilled spirits, wine, or malt beverages, as those terms are defined or used
				  in R.I. Gen. Laws Chapter 3- 1, nor tobacco.
2. "Department" means the Rhode Island
				  Department of Health.
3.
				  "Nonresident pharmacy" means a pharmacy located outside Rhode Island in any
				  state in the United States or any province or territory of Canada that ships,
				  mails, or delivers prescription drugs and/or devices to a patient or person in
				  Rhode Island.
4. "Parent or legal
				  guardian" means the custodial parent for a person under eighteen (18) years of
				  age or the legal guardian with responsibility for health care decisions for a
				  person of any age.
5. "Pharmacy"
				  means that portion or part of a premise where prescriptions are compounded and
				  dispensed, including that portion utilized for the storage of prescription or
				  legend drugs.
6. "Practitioner"
				  means a physician, physician assistant, dentist, veterinarian, nurse or other
				  person duly authorized by law in the state in which they practice to prescribe
				  drugs.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 3 - Prescription Drug Monitoring Program (216-RICR-20-20-3) › Section 216-RICR-20-20-3.4 - General Requirements

Current through June 14, 2024
A. A pharmacy
				  licensed as a retail pharmacy that dispenses schedule II, III, IV, or V
				  controlled substances and opioid antagonists shall transmit prescription
				  dispensing data for these substances to the Department in accordance with
				  §§
										3.5(A) and
				  (B)   of this Part.
1. A pharmacy licensed as an institutional
				  pharmacy that dispenses schedule II, III, IV, or V controlled substances and
				  opioid antagonists shall transmit prescription dispensing data for these
				  substances to the Department when dispensed to outpatients only and shall not
				  be required to submit zero fill reports.
a. A
				  pharmacy that possesses a Rhode Island Controlled Substance Registration (CSR)
				  pursuant to R.I. Gen. Laws §
												21-28-3.02(a) 
				  which does not dispense any controlled substances shall report "zero fills,"
				  every twenty-four (24) hours.
b.
				  Any pharmacy that does not possess a Rhode Island Controlled Substance
				  Registration (CSR) is not required to submit "zero fills"
				  reports.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 3 - Prescription Drug Monitoring Program (216-RICR-20-20-3) › Section 216-RICR-20-20-3.5 - Reporting and Management of Information

Current through June 14, 2024
A. A pharmacy
				  that dispenses schedule II, III, IV, or V controlled substances or opioid
				  antagonists to a person, who is not an inpatient of a hospital, shall transmit
				  electronically to the Department the following information:
1. Pharmacy Drug Enforcement Administration
				  identification number;
2. Patient
				  last name;
3. Patient first
				  name;
4. Patient street address,
				  including zip code;
5.
				  City;
6. State;
7. Date of birth;
8. Gender code;
9. Prescription species code;
10. Prescription number;
11. Date prescription written;
12. Number of refills authorized;
13. Date prescription filled;
14. Refill number;
15. National Drug Code number;
16. Quantity dispensed;
17. Days' supply;
18. Payment code for either cash or
				  third-party provider; and
19.
				  Prescriber Drug Enforcement Administration identification number.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 3 - Prescription Drug Monitoring Program (216-RICR-20-20-3) › Section 216-RICR-20-20-3.6 - Management of Information

Current through June 14, 2024
A. The Department
				  shall only disclose information obtained pursuant to this Part in accordance
				  with R.I. Gen. Laws §
										21-28-3.32(a).
B. A patient may request from the dispensing
				  pharmacy correction of any inaccurate information contained within the
				  prescription drug monitoring database in accordance with the procedure
				  specified by R.I. Gen. Laws §
										5-37.3-5(c).
C. Maintenance of records of information
				  disclosed is pursuant to R.I. Gen. Laws §
										21-28-3.32(e).
D. Removal of prescription information
				  contained within the prescription drug monitoring database is pursuant to R.I.
				  Gen. Laws §
										21-28-3.32(f).
E. Notification of improper disclosure is
				  pursuant to R.I. Gen. Laws §
										21-28-3.32(g).
F. Notification to patients of the
				  prescription drug monitoring program is pursuant to R.I. Gen. Laws §
										21-28-3.32(h).
G. Department disclosure of information to
				  patients is pursuant to R.I. Gen. Laws §
										21-28-3.32(c).
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 3 - Prescription Drug Monitoring Program (216-RICR-20-20-3) › Section 216-RICR-20-20-3.7 - Storage of Information

Current through June 14, 2024
A. The Department
				  shall ensure the privacy of patients and confidentiality of patient information
				  transmitted or obtained is maintained in accordance with applicable state and
				  federal laws, rules, and regulations.
1. No
				  person shall access information in the prescription monitoring database except
				  to the extent and for the purposes authorized by §
											3.6(A)   of
				  this Part.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 3 - Prescription Drug Monitoring Program (216-RICR-20-20-3) › Section 216-RICR-20-20-3.8 - Evaluation

Current through June 14, 2024
The Department may evaluate the prescription information
					 received from pharmacies for the purposes of preventing controlled substance
					 diversion, public health initiatives, and statistical
					 reporting.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 3 - Prescription Drug Monitoring Program (216-RICR-20-20-3) › Section 216-RICR-20-20-3.9 - Delegation of Access to the Electronic Prescription Database

Current through June 14, 2024
A. Notwithstanding the provisions of §
										3.6(A)   of
				  this Part, a pharmacist or prescriber is allowed to share access to the
				  prescription drug monitoring database with an authorized designee of the
				  practitioner and/or pharmacist, to consult the prescription drug monitoring
				  database on the practitioner's and/or pharmacist's behalf, provided that the
				  requirements of R.I. Gen. Laws §21-28-3.3.32 (a)(3) are
				  satisfied.
B. The actual user name
				  and password that is used will be that of the pharmacist or prescriber and
				  shared solely at the discretion of the professional.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 4 - Pain Management, Opioid Use and the Registration of Distributors of Controlled Substances in Rhode Island › Section 216-RICR-20-20-4.1 - Authority

Current through June 14, 2024
These regulations are promulgated pursuant to the authority
					 conferred under R.I. Gen. Laws §
										21-28-3.01,
					 for the purpose of establishing minimum requirements for pain management and
					 opioid prescribing by a practitioner, and requiring registration of every
					 person who manufactures, distributes, prescribes, administers or dispenses any
					 controlled substance within Rhode Island.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 4 - Pain Management, Opioid Use and the Registration of Distributors of Controlled Substances in Rhode Island › Section 216-RICR-20-20-4.2 - Incorporated Materials

Current through June 14, 2024
These regulations hereby adopt and incorporate  21 C.F.R. §
											1311  (Requirements for Electronic Orders and Prescriptions) (2018) by
					 reference, not including any further editions or amendments thereof and only to
					 the extent that the provisions therein are not inconsistent with these
					 regulations.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 4 - Pain Management, Opioid Use and the Registration of Distributors of Controlled Substances in Rhode Island › Section 216-RICR-20-20-4.4 - Pain Management and Prescribing

Current through June 14, 2024
A. Patient
				  Evaluation. The practitioner shall obtain, evaluate and document the patient's
				  health history and physical examination in the health record prior to treating
				  for chronic pain.
B. Documentation
				  of Treatment Plan. Documentation in the medical record for chronic pain shall
				  state the objectives that will be used to determine treatment success and shall
				  include, at a minimum:
1. Any change in pain
				  relief;
2. Any change in physical
				  and psychosocial function; and
3.
				  Additional diagnostic evaluations or other planned treatments.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 4 - Pain Management, Opioid Use and the Registration of Distributors of Controlled Substances in Rhode Island › Section 216-RICR-20-20-4.5 - Registration Requirements

Current through June 14, 2024
A. Pursuant to R.I.
				  Gen. Laws §
										21-28-3.02(a),
				  every person who manufactures, distributes, prescribes, administers, or
				  dispenses any controlled substance within Rhode Island, or who proposes to
				  engage in the manufacture, distribution, prescribing, administering, or
				  dispensing of any controlled substance within Rhode Island, must obtain a
				  registration, issued by the Director, at intervals not to exceed two (2) years,
				  unless exempt in accordance with R.I. Gen. Laws §
										21-28-3.30.
1. Application for registration may be
				  obtained at:
Rhode Island Department of Health - Board of
					 Pharmacy
Three Capitol Hill, Room 205
Providence, RI 02908
2. An applicant for registration shall comply
				  with the federal registration requirements set forth by the federal Drug
				  Enforcement Administration, Department of Justice (or successor
				  agency).
3. In addition to all
				  other applicable requirements of this Part, an applicant for a distributor
				  registration must hold a current Rhode Island state license for distribution of
				  drugs, medicines and poisons, issued by the Rhode Island Board of Pharmacy,
				  pursuant to the provisions of R.I. Gen. Laws Chapter 5-19.1 and the rules and
				  regulations pertaining to Pharmacists, Pharmacies and Manufacturers,
				  Wholesalers, and Distributors (Part
				  40-15-1 of this
				  Title).
4. The ability of an
				  applicant or registrant to maintain effective controls against diversion, as
				  required pursuant to §
											4.6   of this Part, will be
				  considered by the Director in determining whether issuance of a registration is
				  consistent with the public interest.
5. A filing fee, as set forth in the Fee
				  Structure for Licensing, Laboratory, and Administrative Services Provided by
				  the Department of Health (Part 10-05-2 of this Title), is required for all
				  classes of registration.
6. All
				  practitioners shall, as a condition of the initial registration or renewal of
				  the practitioner's authority to prescribe controlled substances, register with
				  the PDMP.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 4 - Pain Management, Opioid Use and the Registration of Distributors of Controlled Substances in Rhode Island › Section 216-RICR-20-20-4.6 - Limitation on Registration

Current through June 14, 2024
A. The registration
				  issued by the Department shall limit distribution to controlled substances
				  permitted by the applicant's federal registration.
B. Distributors may not distribute controlled
				  substances labeled "Physician's Sample", "Complimentary", "Physician's Sample -
				  Not to be Sold", "Complimentary Package", "Patient Starter Package",
				  "Professional Sample", or any other designation indicating other than a trade
				  package available for resale by, or to, a registrant in the public
				  interest.
C. Nothing in this Part
				  shall prohibit a distributor from distributing controlled substances to a
				  practitioner, upon required order forms, by means of common, contract, or
				  interstate carrier, at the usual and customary cost, or as a gift.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 4 - Pain Management, Opioid Use and the Registration of Distributors of Controlled Substances in Rhode Island › Section 216-RICR-20-20-4.7 - General Security Requirements

Current through June 14, 2024
A. All applicants
				  and registrants shall provide effective controls and procedures to guard
				  against theft and diversion of controlled substances.
B. In determining whether an applicant or
				  registrant has demonstrated maintenance of effective security controls pursuant
				  to R.I. Gen. Laws §
										21-28-3.28,
				  the Director may consider, but not be limited to, the following factors:
1. The type of activity conducted;
2. The type and form of controlled substances
				  handled;
3. The quantity of
				  controlled substances handled;
4.
				  The location of the premises and the relationship such location bears on
				  security needs;
5. The type of
				  building construction comprising the facility and the general characteristics
				  of the building or buildings;
6.
				  The type of vault, safe, and secure enclosures or other storage system
				  used;
7. The type of closures on
				  vaults, safes, and secure enclosures;
8. The adequacy of key control systems and/or
				  combination lock control systems;
9. The adequacy of electric detection and
				  alarm systems, if any including use of supervised transmittal lines and standby
				  power sources;
10. Method sought to
				  be used for transportation of said controlled substance being distributed
				  (e.g., common carrier, contract carrier, interstate carrier, private carrier,
				  or other);
11. The extent of
				  unsupervised public access to the facility, including the presence and
				  characteristics of perimeter fencing, if any;
12. The adequacy of supervision over
				  employees having access to manufacturing and storage areas;
13. The procedures for handling business
				  guests, visitors, maintenance personnel, and nonemployee service
				  personnel;
14. The availability of
				  local police protection or of the registrant's or applicant's security
				  personnel;
15. Recordkeeping
				  requirements of the Act;
16. Drug
				  destruction requirements of the Act;
17. The adequacy of the registrant's or
				  applicant's system for monitoring the receipt, manufacture, distribution, and
				  disposition of controlled substances in its operations;
18. The applicability of the security
				  requirements contained in all Federal and Rhode Island laws and regulations
				  governing the management of waste;
19. Past experience of the
				  Department;
20. Past patterns of
				  abuse, arrest, and noncompliance by distributors in Rhode Island, drug
				  destruction data, citizen and police complaints, detection of samples, outside
				  of legitimate channels, seizure of misbranded drugs; and
21. Any other factor which would assist the
				  Director to conclude that the registration for each distributor is not
				  inconsistent with the public interest.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 4 - Pain Management, Opioid Use and the Registration of Distributors of Controlled Substances in Rhode Island › Section 216-RICR-20-20-4.8 - Violations and Hearings

Current through June 14, 2024
A. Any person who
				  violates any provision of the Act, or this Part, shall be subject to the
				  penalty provisions as specified in the Act.
B. All hearings and reviews required by this
				  Part shall be held in accordance with the provisions of R.I. Gen. Laws Chapter
				  42-35 and the rules and regulations pertaining to Practices and Procedures
				  Before the Rhode Island Department of Health (Part 10-05-4 of this
				  Title).
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 5 - Opioid Overdose Prevention and Reporting › Section 216-RICR-20-20-5.1 - Authority

Current through June 14, 2024
These rules and regulations are promulgated pursuant to the
					 authority set forth in R.I. Gen. Laws Chapter 23-1, and establish the
					 procedures for administration of an opioid antagonist to an individual
					 experiencing an opioid overdose or suspected overdose, and mandatory procedures
					 for hospitals to report all actual and suspected opioid-related
					 overdoses.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 5 - Opioid Overdose Prevention and Reporting › Section 216-RICR-20-20-5.3 - Prescribing, Dispensing and Administering Opioid Antagonists

Current through June 14, 2024
A. Use of an opioid antagonist in accordance
				  with this Part shall be considered first aid or emergency treatment for the
				  purpose of any statute relating to liability.
B. Notwithstanding any other law or
				  Regulation, any person may lawfully possess opioid antagonists.
C. Notwithstanding any other law or
				  Regulation, any healthcare professional may dispense opioid antagonists,
				  consistent with the provisions of this Part.
D. Any prescription for an opioid antagonist
				  shall be regarded as being issued for a legitimate medical purpose in the usual
				  course of professional practice.
5.3.1
Prescribing, Dispensing, and
				  Administering Opioid Antagonists by Healthcare Professionals
A. Opioid antagonists may lawfully be
				  prescribed and dispensed to:
1. Any person at
				  risk of experiencing an opioid-related overdose; and
2. Any person or persons, such as a family
				  member or friend of a person at risk of experiencing an opioid-related
				  overdose, who is reasonably expected by the prescriber to be in a position to
				  respond to such person at risk of experiencing an opioid-related
				  overdose.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 5 - Opioid Overdose Prevention and Reporting › Section 216-RICR-20-20-5.4 - Reporting Requirements

Current through June 14, 2024
A. Hospitals in
				  which medical care for an opioid-related drug overdose is provided or sought to
				  be provided, shall report the opioid-related drug overdose using the reporting
				  format approved by the Department, within forty-eight (48) hours of initial
				  contact with the patient. Such report shall include any results of drug
				  screening/testing performed on a patient who experienced an opioid-related drug
				  overdose. Any additional pertinent information, including patient's name, date
				  of birth, address, and any retrospective data not previously provided, which is
				  requested by the Department after the initial reported case, shall be reported
				  to the Department promptly upon request.
1.
				  Reports regarding an opioid-related drug overdose shall be submitted utilizing
				  a secure means of data transfer determined by the Department
2. Data collected under §
											5.4(A)   of
				  this Part may be used by the Department for the purposes of conducting program
				  and policy evaluation, and research as approved by the Department's
				  Institutional Review Board. Data collected pursuant to §
											5.4(A)   of
				  this Part may be linked to other data accessible to the Department for those
				  purposes.
3. Data under §
											5.4(A)   of
				  this Part shall not be shared with law enforcement.
4. Data collected under §
											5.4(A)   of
				  this Part shall not be shared with third party payers, or other entities
				  outside of the Department for activities outside of Department approved
				  evaluation, surveillance and research.
a.
				  Exception. Data shall be shared with the Director of BHDDH or his or her
				  designee in accordance with the inter-agency memorandum of
				  understanding.
5. Data
				  collected under §
											5.4(A)   of
				  this Part are not public information. The collection, storage, use, or sharing
				  of any data obtained pursuant to this Part shall be in accordance with all
				  applicable State and Federal law, including the Confidentiality of Health Care
				  Information Act (R. I. Gen. Laws §§
											5-37.3-1
et
				  seq.
), the Health Insurance Portability and Accountability Act
				  (including all effective Regulations promulgated thereunder), the Identify
				  Theft Protection Act of 2015 (R. I. Gen. Laws §§
											11-49.3-1
et seq.
), and all other applicable laws. Any transfer of these
				  data must meet State data encryption policy.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 5 - Opioid Overdose Prevention and Reporting › Section 216-RICR-20-20-5.5 - Severability

Current through June 14, 2024
If any provisions herein or the application thereof to any
					 person or circumstance shall be held invalid, such invalidity shall not affect
					 the provisions or application herein which can be given effect, and to this end
					 the provisions herein are declared to be severable.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 6 - Off Label Prescribing of Medications for COVID-19 › Section 216-RICR-20-20-6.1 - Authority

Current through June 14, 2024
These Regulations are promulgated pursuant to the authority
					 conferred under R.I. Gen. Laws §§
										23-1-1 and
					  23-1-18 and are established for the purpose of allowing off-label prescribing to treat
					 COVID-19.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 6 - Off Label Prescribing of Medications for COVID-19 › Section 216-RICR-20-20-6.2 - Definitions

Current through June 14, 2024
A. Wherever used in this Part, the terms
				  listed below shall be construed in the following manner:
1. "COVID-19" means the disease caused by
				  novel coronavirus SARS-CoV-2.
2.
				  "Off-label prescribing" means the prescribing of an FDA-approved medication for
				  reasons other than indicated or approved by the FDA.
3. "Practitioner" means any person licensed
				  in the state of Rhode Island to provide health care services and to prescribe
				  medication.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 20 - Community Health › Subchapter 20 - Drugs › Part 6 - Off Label Prescribing of Medications for COVID-19 › Section 216-RICR-20-20-6.3 - Off-Label Prescribing of Medications for Treatment or Prevention of COVID-19

Current through June 14, 2024
A. No practitioner
				  shall prescribe any medication for COVID-19, either for treatment or
				  prevention, unless treatment or prevention of COVID-19, or similar infectious
				  disease, is within such practitioner's usual and customary scope of
				  practice.
B. Any practitioner who
				  chooses to prescribe an FDA-approved medication for the off-label purpose of
				  treating COVID-19 shall:
1. Indicate on the
				  prescription the applicable ICD-10 diagnosis code.
2. Indicate on the prescription a telephone
				  number at which the dispensing authority (e.g., pharmacist) may reach the
				  health care provider to address questions relative to dose and
				  treatment.
3. Document in the
				  associated patient's medical record that the specific risks and benefits of the
				  off-label treatment were discussed with the patient.
4. Document in the associated patient's
				  medical record the clinical rationale for the off-label prescribing, citing:
a. At least one (1) peer-reviewed article
				  that justifies the clinical decision for the off-label prescribing, in the
				  event that the FDA publishes such guidance; or
b. Applicable FDA guidance justifying the
				  clinical decision for the off-label prescribing, in the event that the FDA
				  publishes such guidance.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 30 - Infectious Diseases › Subchapter 05 - Infectious Diseases › Part 1 - Reporting and Testing of Infectious, Environmental, and Occupational Diseases › Section 216-RICR-30-05-1.1 - Authority

Current through June 14, 2024
These Regulations are promulgated pursuant to the authority
					 conferred under R.I. Gen. Laws §§
										23-1-1 and
					  23-8-1 for the purpose of adopting prevailing standards for confidentiality and
					 reporting of infectious, occupational, and environmentally related diseases in
					 Rhode Island.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 30 - Infectious Diseases › Subchapter 05 - Infectious Diseases › Part 1 - Reporting and Testing of Infectious, Environmental, and Occupational Diseases › Section 216-RICR-30-05-1.2 - Incorporated Materials

Current through June 14, 2024
A. These
				  Regulations hereby adopt and incorporate HIPAA Privacy Rule and Public Health:
				  Guidance from CDC and the U.S. Department of Health and Human Services May 2,
				  2003/52 (S-1); 1-12. by reference, not including any further editions or
				  amendments thereof and only to the extent that the provisions therein are not
				  inconsistent with these Regulations.
B. These Regulations hereby adopt and
				  incorporate The American Society of Microbiology Sentinel Level Clinical
				  Laboratory Protocols for Suspected Biological Threat Agents and Emerging
				  Infectious Diseases 2013 for Botulinum Toxin, Novel Influenza Viruses,
				  Smallpox, and Staph Enterotoxin B by reference, not including any further
				  editions or amendments thereof and only to the extent that the provisions
				  therein are not inconsistent with these Regulations.
C. These Regulations hereby adopt and
				  incorporate The American Society of Microbiology Sentinel Level Clinical
				  Laboratory Protocols for Suspected Biological Threat Agents and Emerging
				  Infectious Diseases 201 6 for
Bacillus anthracis
,
Brucella
,
Burkholderia
(mallei and
				  pseudomallei),
Coxiella burnetii
,
Yersinia
				  pestis
, and
Francisella tularensis
by reference, not
				  including any further editions or amendments thereof and only to the extent
				  that the provisions therein are not inconsistent with these
				  Regulations.
D. These Regulations
				  hereby adopt and incorporate The American National Standards Institute CLSI
				  M48-A "Laboratory Detection and Identification of Mycobacteria Approved
				  Guideline" 2008 by reference, not including any further editions or amendments
				  thereof and only to the extent that the provisions therein are not inconsistent
				  with these Regulations.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 30 - Infectious Diseases › Subchapter 05 - Infectious Diseases › Part 1 - Reporting and Testing of Infectious, Environmental, and Occupational Diseases › Section 216-RICR-30-05-1.4 - Confidentiality Provisions

Current through June 14, 2024
A. All information
				  concerning cases or suspected cases shall be held in confidence in accordance
				  with the provisions of R.I. Gen Laws §
										5-37-3 and all other applicable State and Federal statutes and Regulations.
B. Pursuant to the HIPAA Privacy Rule,
				  disclosures to RIDOH without individual authorization are permitted for the
				  purpose of preventing or controlling disease, injury, or disability, including
				  but not limited to public health surveillance, investigation, and intervention.
1.4.1
Persons and Entities Responsible
				  for Reporting Diseases
A. The
				  following individuals and entities attending the case or suspected case are
				  required to report the diseases listed in § 1.5.3 of this Part:
1. Physicians
2. Physician assistants
3. Certified registered nurse
				  practitioners
4. Clinical
				  laboratories
5. Hospitals (from
				  both inpatient and outpatient settings)
a.
				  When a diagnosis or suspected diagnosis of a case is made within a hospital,
				  the facility administrator, or his/her designee (e.g., infection control
				  practitioner), must ensure the reporting of the case in accordance with the
				  procedures outlined in these Regulations.
6. All other health care facilities,
				  including but not limited to: organized ambulatory care facility, school-based
				  health center, college/university-health center, freestanding emergency care
				  facility, home care/home nursing care provider, hospice, birth center, nursing
				  facility, rehabilitation hospital center, freestanding ambulatory surgical
				  center, kidney disease treatment center, blood centers, and prison health
				  services.
a. When a diagnosis or suspected
				  diagnosis of a case is made within a licensed health care facility, the
				  facility administrator or medical director, or his/her designee (e.g.,
				  infection control practitioner), must ensure the reporting of the case in
				  accordance with the procedures outlined in these Regulations.
7. Veterinarians who have
				  knowledge of: a single case of rare and/or unusual veterinary diagnosis that
				  has the potential to cause illness in humans, or knowledge of outbreaks of
				  unusual zoonotic vectorborne diseases that can cause illness in
				  humans;
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 30 - Infectious Diseases › Subchapter 05 - Infectious Diseases › Part 1 - Reporting and Testing of Infectious, Environmental, and Occupational Diseases › Section 216-RICR-30-05-1.5 - Timeframe, Methods, and Reportable Conditions

Current through June 14, 2024
1.5.1
Timeframes
A. The lists cited in
				  § 1.5.3 of this Part pertain to individuals and facilities required to
				  report pursuant to § 1.4.1 of this Part. Cases due to the diseases listed
				  below shall be reported to the RIDOH within the timelines indicated. Reportable
				  diseases are grouped as follows:
1.
				  Immediately reportable diseases shall be reported within twenty-four (24) hours
				  of recognition or strong suspicion of disease.
2. All other reportable conditions shall be
				  reported within four (4) days of recognition or suspicion.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 30 - Infectious Diseases › Subchapter 05 - Infectious Diseases › Part 1 - Reporting and Testing of Infectious, Environmental, and Occupational Diseases › Section 216-RICR-30-05-1.6 - Special Disease Surveillance Projects

Current through June 14, 2024
A.
				  Reporting will be required for surveillance related to special and/or complex
				  surveillance systems (e.g., Zika, latent TB infection, influenza, new and
				  emerging disease threats, and evaluation and validation projects related to
				  surveillance) at the discretion of RIDOH.
B. Reporting will be required for any
				  additional surveillance systems that are developed and implemented to prepare
				  for or respond to public health threats at the discretion of RIDOH at any
				  time.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 30 - Infectious Diseases › Subchapter 05 - Infectious Diseases › Part 1 - Reporting and Testing of Infectious, Environmental, and Occupational Diseases › Section 216-RICR-30-05-1.7 - Instructions for Laboratories

Current through June 14, 2024
1.7.1
General
				  Instructions
A. Whenever a Rhode Island
				  licensed clinical laboratory performs tests or has the sample(s) tested out of
				  State for those diseases cited in § 1.5.3 of this Part, the laboratory
				  shall submit to RIDOH all positive findings.
B. Negative laboratory results for those
				  diseases cited in § 1.5.3 of this Part, must be reported for public health
				  surveillance and investigation purposes at the discretion of RIDOH.
C. The report shall consist of a copy of the
				  laboratory findings submitted to the physician or other licensed health care
				  provider who ordered the test. This report shall indicate the name of the case,
				  address of the case, gender, date of birth, telephone number, race, ethnicity,
				  and name of attending physician.
D.
				  All genotyping, molecular detection, and phylogenetic testing results on
				  reportable conditions must be reported to RIDOH.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 30 - Infectious Diseases › Subchapter 05 - Infectious Diseases › Part 1 - Reporting and Testing of Infectious, Environmental, and Occupational Diseases › Section 216-RICR-30-05-1.8 - Reporting of Environmental Exposures and Occupational Diseases

Current through June 14, 2024
1.8.1
Persons and Entities Attending
				  the Case or Suspected Case Responsible for Reporting Environmental Exposures
				  and Occupational Diseases
A.
				  Physicians
B. Physician
				  assistants
C. Certified registered
				  nurse practitioners
D. Clinical
				  laboratories
E. Hospitals (from
				  both inpatient and outpatient settings)
1.
				  When a diagnosis or suspected diagnosis of a case is made within a hospital,
				  the facility administrator, or his/her designee (e.g., infection control
				  practitioner), must report occupational diseases and exposures.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 30 - Infectious Diseases › Subchapter 05 - Infectious Diseases › Part 3 - Immunization and Communicable Disease Testing in Preschool, School, Colleges or Universities (216-RICR-30-05-3) › Section 216-RICR-30-05-3.1 - Authority

Current through June 14, 2024
A. These regulations are promulgated pursuant
				  to R.I. Gen. Laws §§
										16-38-2 and
				   23-1-18 and are established for the purpose of adopting standards pertaining to
				  requirements for immunizations and testing of communicable diseases for child
				  care workers in preschools and students at any preschool or school in grades
				  Kindergarten-12 and students entering colleges and universities in Rhode
				  Island.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 30 - Infectious Diseases › Subchapter 05 - Infectious Diseases › Part 3 - Immunization and Communicable Disease Testing in Preschool, School, Colleges or Universities (216-RICR-30-05-3) › Section 216-RICR-30-05-3.2 - Incorporated Materials

Current through June 14, 2024
A. These
				  regulations hereby adopt and incorporate the Centers for Disease Control and
				  Prevention (CDC) General Recommendations on Immunization: Recommendations of
				  the Advisory Committee on Immunization Practices (ACIP), MMWR, Recommendations
				  and Reports (January 2011) by reference, not including any further editions or
				  amendments thereof and only to the extent that the provisions therein are not
				  inconsistent with these regulations.
				  https://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf
B. These regulations hereby adopt and
				  incorporate the "Rhode Island Department of Health Rules and Regulations
				  Pertaining to the Reporting of Communicable, Environmental and Occupational
				  Diseases" (November 2013) by reference, not including any further editions or
				  amendments thereof and only to the extent that the provisions therein are not
				  inconsistent with these regulations.
http://sos.ri.gov/documents/archives/regdocs/released/pdf/DOH/7434.pdf
C. These regulations hereby adopt and
				  incorporate the "CDC Guidelines for Targeted Tuberculin Testing and Treatment
				  of Latent Tuberculosis Infection MMWR, Recommendations and Reports" (June 2000)
				  by reference, not including any further editions or amendments thereof and only
				  to the extent that the provisions therein are not inconsistent with these
				  regulations.
https://www.cdc.gov/mmwr/PDF/rr/rr4906.pdf
D. These regulations hereby adopt and
				  incorporate the "National Resource Center for Health and Safety in Childcare
				  and Early Education's Guidelines for Early Care and Education Programs"
				  (October 2015) by reference, not including any further editions or amendments
				  thereof and only to the extent that the provisions therein are not inconsistent
				  with these regulations.
				  http://cfoc.nrckids.org/WebFiles/CFOC3_updated_final.pdf
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 30 - Infectious Diseases › Subchapter 05 - Infectious Diseases › Part 3 - Immunization and Communicable Disease Testing in Preschool, School, Colleges or Universities (216-RICR-30-05-3) › Section 216-RICR-30-05-3.4 - General Requirements

Current through June 14, 2024
A. Preschools and
				  schools shall adopt, at a minimum, the standards of immunization and
				  communicable disease testing in §
										3.5   of this Part.
1. It shall be the responsibility of the
				  administrative head or his/her designee of any preschool or school to secure
				  compliance with these Regulations.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 30 - Infectious Diseases › Subchapter 05 - Infectious Diseases › Part 3 - Immunization and Communicable Disease Testing in Preschool, School, Colleges or Universities (216-RICR-30-05-3) › Section 216-RICR-30-05-3.5 - Minimum Standards for Immunization and Communicable Disease Testing for Students Entering Preschools and Schools (K-12)

Current through June 14, 2024
A. Each student, upon initial entry to any
				  preschool or school in Rhode Island, shall furnish evidence to the
				  administrative head of the preschool or school (pursuant to the requirements of
				  §3.5.3 of this Part) that the student has been immunized, as required in
				  §§3.5.1(A)(1)(a) and 3.5.2(A) ( 1-7) of this Part, unless the student
				  is in an exempt category.
1. For the
				  immunization requirements stipulated in §§3.5.1-(A)(1)(a) and
				  3.5.2(A) of this Part, a student who is not in compliance with these
				  requirements shall be excluded from attending preschool or school until the
				  requirements are met, unless the student belongs in an exemption category or is
				  in a waiting period between doses as described in §3.5.4 of this
				  Part.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 30 - Infectious Diseases › Subchapter 05 - Infectious Diseases › Part 3 - Immunization and Communicable Disease Testing in Preschool, School, Colleges or Universities (216-RICR-30-05-3) › Section 216-RICR-30-05-3.6 - Minimum Standards for Immunization and Communicable Disease Testing for Students Entering Colleges or Universities

Current through June 14, 2024
A.
				  Each student, upon entering any college or university in Rhode Island, shall
				  furnish evidence to the administrative head of the college or university
				  (pursuant to the requirements of §3.6.2 of this Part) that the student has
				  been immunized, as required in §3.6.1 of this Part, unless the student is
				  in an exempt category (e.g., documented evidence of immunity).
B. For the immunization requirements
				  stipulated in §3.6.1 of this Part, a student who is not in compliance with
				  these requirements shall be excluded from attending college or university
				  classes until the requirements are met, unless the student belongs in an
				  exemption category or is in a waiting period between doses as described in
				  §3.6.3(B) or §3.6.3(C) of this Part.
3.6.1
College or University Entry:
				  Immunization Requirements
A. Each
				  student, upon entering any college or university, shall furnish evidence as
				  required in §3.6.2 of this Part of having received the vaccines described
				  below:
1. Tetanus, Diphtheria, Pertussis
				  Vaccine. Evidence of having received a single dose of Tdap vaccine.
2. Measles, Mumps, and Rubella Vaccines. Two
				  (2) doses of live measles, mumps and rubella vaccine given at least four (4)
				  weeks apart beginning on or after twelve (12) months of age.
3. Hepatitis B Vaccine. Three (3) doses of
				  hepatitis B vaccine administered in accordance with ACIP
				  recommendations.
4. Varicella
				  (Chickenpox) Vaccine. Two (2) doses of varicella vaccine given at least four
				  (4) weeks apart beginning on or after twelve (12) months of age.
5. Meningococcal Vaccine. Beginning August 1,
				  2015, one (1) dose of meningococcal conjugate (MCV4) vaccine in the last 5
				  years is required for previously unvaccinated newly enrolled full-time
				  undergraduate and graduate students (under twenty-two (22) years of age) in a
				  degree program at a college or university who will live in a dormitory or
				  comparable congregate living arrangement approved by the institution.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 30 - Infectious Diseases › Subchapter 05 - Infectious Diseases › Part 3 - Immunization and Communicable Disease Testing in Preschool, School, Colleges or Universities (216-RICR-30-05-3) › Section 216-RICR-30-05-3.7 - Tuberculosis Testing for Colleges/Universities

Current through June 14, 2024
A.
				  Targeted tuberculosis (TB) testing is required for entering students who are
				  from highly endemic countries of the world and have been a resident in the
				  United States for less than five (5) years. All other testing should be
				  conducted according to the CDC Guidelines incorporated above at §
										3.2(C)   of
				  this Part.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 30 - Infectious Diseases › Subchapter 05 - Infectious Diseases › Part 3 - Immunization and Communicable Disease Testing in Preschool, School, Colleges or Universities (216-RICR-30-05-3) › Section 216-RICR-30-05-3.8 - Minimum Standards for Immunization and Communicable Disease Testing for Child Care Workers in Preschools

Current through June 14, 2024
A. Beginning August
				  1, 2015, in accordance with the National Health and Safety Performance
				  Standards for Early Care and Education Programs incorporated above at §
										3.2(D)   of
				  this Part, evidence of immunity is required for all child care workers (with
				  the exception of child care workers who receive a medical exemption) against:
1. Tetanus, Diphtheria and Pertussis: one (1)
				  dose of Tdap vaccine
2. Measles,
				  Mumps and Rubella: two (2) doses of MMR vaccine
3. Chickenpox: two (2) doses of Varicella
				  vaccine
4. Influenza: annual
				  influenza vaccination, administered between July 1 and December 31 of each
				  year, is required for all child care workers
5. Acceptable evidence of completion of
				  immunization consists of:
a. An official
				  immunization record card, school immunization record, Medical Passport, World
				  Health Organization immunization record, or other official immunization records
				  acceptable to the Department; or
b.
				  An electronically stored and/or transmitted documentary record (facsimile
				  transmission, computerized record, including, but not limited to, a record on
				  magnetic media or similar record) as may be utilized by a school; or
c. Presentation of laboratory evidence of
				  immunity is made in the case of measles, mumps, rubella, hepatitis B, and
				  varicella (chickenpox); or
d. A
				  physician, physician assistant, certified registered nurse practitioner, or
				  other licensed practitioner acting within his/her scope of practice signs a
				  statement that the student has a history of chickenpox disease
				  (varicella).
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 30 - Infectious Diseases › Subchapter 05 - Infectious Diseases › Part 3 - Immunization and Communicable Disease Testing in Preschool, School, Colleges or Universities (216-RICR-30-05-3) › Section 216-RICR-30-05-3.9 - Reporting

Current through June 14, 2024
A. The administrative head (or designee) of
				  each preschool, school, college and university shall be responsible for
				  reporting the immunization status of students and the number of students with a
				  medical and/or religious exemption to the Department.
B. Such reporting shall occur according to
				  procedures and format required by the Department.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 30 - Infectious Diseases › Subchapter 05 - Infectious Diseases › Part 3 - Immunization and Communicable Disease Testing in Preschool, School, Colleges or Universities (216-RICR-30-05-3) › Section 216-RICR-30-05-3.10 - Severability

Current through June 14, 2024
A. If any provisions of these Regulations or
				  the application thereof to any facility or circumstances shall be held invalid,
				  such invalidity shall not affect the provisions or application of these
				  Regulations which can be given effect, and to this end the provisions of these
				  Regulations are declared to be severable.
Rhode Island Code of Regulations › Title 216 - Department of health › Chapter 40 - Professional licensing and facility regulation › Subchapter 05 - Professional Licensing › Part 1 - Licensure and Discipline of Physicians (216-RICR-40-05-1) › Section 216-RICR-40-05-1.1 - Authority and Incorporated Materials

Current through June 14, 2024
1.1.1
Authority
These Regulations are promulgated pursuant to the authority
					 conferred under R.I. Gen. Laws §§
											5-37-1.4(5)  and
					  5-19.2-3, and are established for
					 the purpose of updating prevailing standards governing the licensure and
					 discipline of physicians in Rhode Island.
1.1.2
Incorporated Materials
These Regulations hereby adopt and incorporate by reference
					 the Centers for Disease Control ("CDC") "Guide to Infection Prevention for
					 Outpatient Settings: Minimum Expectations for Safe Care" (September 2016), not
					 including any further editions or amendments thereof, and only to the extent
					 that the provisions therein are not inconsistent with this
					 Part.